HIV-1 infection in infants and the unidentified susceptibility of white blood cells for retroviral infection

HIV-1 infection in infants and the unidentified susceptibility of white blood cells for retroviral infection - HIV-1 infection in infants

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30327

Enrollment

Registered

2006-12-04

Start date

2006-12-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS HIV-1-infection

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy subjects: healthy pregnant women and their newborn baby for cord-blood withdrawal.;Patients: HIV-1-infected pregnant women and their newborn baby for cord-blood withdrawal.

Exclusion criteria

Exclusion criteria: Healthy subjects: 1. infected with a (chronic) infection 2. immune system altering disease 3. immune system altering medication;Healthy and HIV-1-infected mothers: 4. preterm delivery at less than 33 weeks

Design outcomes

Primary

Measure	Time frame
1. CCR5, other chemokine receptor and phenotype expression on cells derived from cord blood of healthy neonates and cord blood from neonates born to HIV-1-infected mothers. 2. define chemokine receptor upregulation as well as phenotype alterations in cells from cord blood by proliferative stimulation via a.o. cytokines (e.g. IL-2, IL-7). 3. determine productive HIV-1 infection rates in vitro of naïve T cells and other white blood cells derived from cord blood of healthy neonates and cord blood from neonates born to HIV-1-infected mothers. 4. Test whether infection (3.) can be inhibited by CCR5 antagonists and monoclonal antibodies against other chemokines receptors. 5. rate of infection of the above cells isolated from the two sets of cord blood with HIV-1 strains obtained from HIV-1 infected children. 6. assess the repertoire of co-receptors for HIV-1 infection on CD4+ T cells and other white blood cells from young patients, i.e. CCR5, CCR2 and CXCR4 expression in the perspective of extensive subset definition of T cells (memory / naïve etc) 7. define the genomic form of HIV-1 in the subsequent white blood cells of HIV-infected infants, e.g. comparing the form of HIV-1 in naïve, memory T cell subsets as well as blood monocytes.	—

Measure

Time frame

1. CCR5, other chemokine receptor and phenotype expression on cells derived from cord blood of healthy neonates and cord blood from neonates born to HIV-1-infected mothers. 2. define chemokine receptor upregulation as well as phenotype alterations in cells from cord blood by proliferative stimulation via a.o. cytokines (e.g. IL-2, IL-7). 3. determine productive HIV-1 infection rates in vitro of naïve T cells and other white blood cells derived from cord blood of healthy neonates and cord blood from neonates born to HIV-1-infected mothers. 4. Test whether infection (3.) can be inhibited by CCR5 antagonists and monoclonal antibodies against other chemokines receptors. 5. rate of infection of the above cells isolated from the two sets of cord blood with HIV-1 strains obtained from HIV-1 infected children. 6. assess the repertoire of co-receptors for HIV-1 infection on CD4+ T cells and other white blood cells from young patients, i.e. CCR5, CCR2 and CXCR4 expression in the perspective of extensive subset definition of T cells (memory / naïve etc) 7. define the genomic form of HIV-1 in the subsequent white blood cells of HIV-infected infants, e.g. comparing the form of HIV-1 in naïve, memory T cell subsets as well as blood monocytes.

—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results